Multicenter phase I studies to evaluate the safety, tolerability, and clinical response to intensive dosing with the proteasome inhibitor PR-171 in patients with relapsed or refractory hematological malignancies Meeting Abstract


Authors: O'Connor, O. A.; Orlowski, R. Z.; Alsina, M.; Stewart, K.; Trudel, S.; Vallone, M. K.; Woo, T. M.; Urquilla, P. R.; Molineaux, C. J.; Goy, A.
Abstract Title: Multicenter phase I studies to evaluate the safety, tolerability, and clinical response to intensive dosing with the proteasome inhibitor PR-171 in patients with relapsed or refractory hematological malignancies
Meeting Title: 48th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 108
Issue: 11 Pt. 1
Meeting Dates: 2006 Dec 9-12
Meeting Location: Orlando, FL
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2006-11-01
Start Page: 687A
End Page: 688A
Language: English
ACCESSION: WOS:000242440003221
PROVIDER: wos
PUBMED: 17139767
Notes: --- - Meeting Abstract: 2430 - 48th Annual Meeting of the American-Society-of-Hematology - DEC 09-12, 2006 - Orlando, FL - Part 1 - "Source: Wos"
MSK Authors